TrialPath

Find a study

Match me to a study

242 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicMental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

149 studies on the map

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma — Allervie Clinical Research, BirminghamStudy of ALTO-300 in MDD — Site 200, PhoenixStudy of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease — University of Illinois at Chicago, ChicagoZelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — University of Alabama at Birmingham, BirminghamCannabidiol in Sickle Cell Disease — Icahn School of Medicine at Mount Sinai, ManhattanA Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) — Noble Clinical Research, TucsonA Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma — Kymera Investigative Site, LancasterA Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder — Harmonex /ID# 277517, DothanDose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids — Research Site, BakersfieldA Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease — University of Alabama at Birmingham, BirminghamA Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor — Neurocrine Clinical Site, BryantA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Velocity Clinical Research, Mobile, MobileALTO-207 in Adults With Treatment-resistant Depression (TRD) — Site 7074, BirminghamPramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disorder (MND) in Persons With HIV — Alabama CRS, BirminghamA Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Clinical Research Site, BellflowerA Study to Evaluate the Effectiveness of DT-101 in Patients With Depression — Draig Clinical Site, BentonvilleA Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder — NoesisPharma, LLC, PhoenixALTO-100 in Bipolar Disorder With Depression (BD-D) — Site 6036, ChandlerACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response — University of Alabama at Birmingham, BirminghamENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults — Enveda Investigative Site, BirminghamA Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma — AMR Clinical, TempeA Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) — Seaport Investigator Site, ChinoA Phase 2/3 Study in Adult and Adolescent Participants With SCD — Smilow Cancer Hospital, New HavenSafety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis — Univ. of California, San Francisco Health Care, OaklandIndividualizing Treatment for Asthma in Primary Care (Full Study) — DARTNet Institute, AuroraA Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma — Research Site, BakersfieldRollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study — University Of Alabama, BirminghamA Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD) — University of Alabama at Birmingham, BirminghamA Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease — University of Alabama Birmingham, BirminghamMinimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease — Children's National Health System, Washington D.C.Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial — UCSF Benioff Children's Hospital Oakland, OaklandSafety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) — UAMS Medical Center, Little RockGene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesA Study of CDX-622 in Participants With Mild to Moderate Asthma — University of California, San Francisco, San FranciscoUse of a Generative AI (Gen-AI) Chatbot for Anxiety and Depression Among Persons With Cannabis Use — 46 Centerra Parkway, Suite 300, Office #333S, LebanonMyeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease — University of California Los Angeles, Los AngelesRuxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell Disease — Children's Hospital of Colorado, AuroraReduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders — Yale School of Medicine, New HavenCombination of Novel Therapies for CKD Comorbid Depression — Stony Brook University Medical Center, Stony BrookLeveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping — Mayo Clinic, ScottsdaleENA-001 for Opioid Induced Respiratory Depression — South Florida Research Phase I-IV, MiamiSCD Stem Cell Mobilization and Apheresis Using Motixafortide — University of Alabama at Birmingham, BirminghamStudy of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders — National Institutes of Health Clinical Center, BethesdaA Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT) — Memorial Sloan Kettering at Basking Ridge (Consent only), Basking RidgeModulating Exercise Dosage to Improve Concussion Recovery — University of Colorado Denver, AuroraMetformin IN Asthma for Overweight and Obese Individuals (MINA) — Johns Hopkins University, BaltimorePhase 1 Study Evaluating Safety and Pharmacokinetics of ASY202 in Adults With Asthma — Sun City Clinical Research, GlendalePramipexole to Enhance Social Connections — University of California, San Diego, San DiegoACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression — Stanford Psychiatry and Behavioral Sciences Department, Palo AltoSearch for Novel Transcranial Magnetic Stimulation (TMS) Targets for Mental Illness — Acacia Clinics, SunnyvaleStudy of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) — Autobahn Site #131, BirminghamA Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) — IMA Clinical Research- Phoenix, PhoenixClinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease — Emory University, AtlantaCHEST: A Collaboration With Community HEalth Centers to Implement SmarT for Asthma — Affinia healthcare, 2220 Lemp Ave, St LouisEscalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease — National Institutes of Health Clinical Center, BethesdaSoy Isoflavones For Inner City Infants At Risk For Asthma (SIRA) Study — Ann and Robert H Lurie Childrens Hospital of Chicago, ChicagoKetamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients — Texas Tech University Health Sciences Center Lubbock, LubbockAβ Dynamics in LLMD — NYU Langone Health, New YorkSubanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients — Mayo Clinic, JacksonvilleFeasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department — University of Kansas Strawberry Hill Campus, Kansas CityGamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression — Wells Medicine, HoustonInflammation and Depression in People With HIV — Grady Memorial Hospital, AtlantaBuspirone and Melatonin for Depression Following Traumatic Brain Injury — Massachusetts General Hospital, BostonA Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression — Draig Clinical Site, DeSotoArginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease — Children's Healthcare fo Atlanta at Hughes Spalding, AtlantaTransplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease — University of California, Los Angeles, Los AngelesEarly Screening and Treatment of Heart Complication in Sickle Cell Disease — Inova Schar Cancer, FairfaxProphylactic Transfusion In Pregnant in Women With Sickle Cell Disease — Grady Health System, AtlantaAllo HSCT for High Risk Hemoglobinopathies — Masonic Cancer Center, MinneapolisA Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease — University of Illinois at Chicago College of Medicine, ChicagoSupplementing L-citrulline to Overweight Late Asthma oNset Phenotypes — Duke University (Asthma, Allergy and Airway Center), DurhamAnti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma — University of Colorado Anschutz Medical Campus, AuroraThe Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) — UCSF Airway Clinical Research Center, San FranciscoKetamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression — VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann ArborHyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease — University of Kansas Medical Center, Kansas CityMechanism(s) of Airflow Limitation During Exacerbation of Asthma — Arthur F Gelb Medical Corporation, LakewoodViral Infection in Asthma (VIA) Study — University of Virginia, CharlottesvilleVENTURI (VENTilation Using Respiratory Imaging) — The University of Alabama at Birmingham, BirminghamA Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study — Kymera Investigative Site, TampaViral Mucosal Reprogramming — University of Texas Medical Branch, GalvestonReslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study — National Jewish Health, Denver5HTP Regulation Of Asthma In Children — Indiana University, IndianapolisStudy to Improve Deployment Related Asthma by Using L-Citrulline Supplementation — National Jewish Health, DenverA Clinical Trial of Soluble Fiber for Asthma — Phoenix Children's, PhoenixMeasuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma — The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh45th Multicenter Airway Research Collaboration — MetroHealth, ClevelandA Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma — Pfizer Clinical Research Unit - New Haven, New HavenAzithromycin for Critical Asthma - Pediatrics — Johns Hopkins All Children's Hospital, St. PetersburgPilot Study to Identify the Mediators and Inflammatory Cell Surface Receptors Involved in Allergic Airway Inflammation — Massachusetts General Hospital, BostonVentilation and Perfusion in Asthmatics — University of Miami - Converge Miami, MiamiOmalizumab Before Onset of Exacerbations — Children's National Hospital, Washington D.C.Escitalopram in Asthma Patients With Frequent Exacerbation — UT Southwestern, 1440 Empire Central, Ste. LD4.100, DallasDetermining Optimal Treatment Sequences in Anxious Depression (DOTS-AD) — University of Cincinnati, Department of Psychiatry & Behavioral Neuroscience, CincinnatiPET Imaging of Vaso-Occlusive Crisis (VOC) in SCD — UPMC, PittsburghAcceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality — The University of Texas Health Science Center at Houston, HoustonIntravenous Ketamine for Treatment-Resistant Depression — Mayo Clinic in Rochester, RochesterMechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression — National Institutes of Health Clinical Center, BethesdaAcceptance and Commitment Therapy for Adolescents and Young Adults With Sickle Cell Disease — Children's Hospital Los Angeles, Los AngelesAlendronate for Osteonecrosis in Adults With Sickle Cell Disease — UC Davis Comprehensive Cancer Center, SacramentoLong-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression — Massachusetts General Hospital, BostonPattern Separation in Major Depressive Disorder — New York State Psychiatric Institute (NYSPI), New YorkEstablishing Multimodal Brain Biomarkers for Treatment Selection in Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinKetamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression — Icahn School of Medicine at Mount Sinai, New YorkNeuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder — National Institutes of Health Clinical Center, BethesdaExamining the Effects of Estradiol on Neural and Molecular Response to Reward — University of North Carolina at Chapel Hill, Chapel HillInvestigation to Understand and Optimize Psilocybin — Vail Health Behavioral Health, EdwardsTRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors — The University of Texas M. D. Anderson Cancer Center, HoustonNeural Circuit Effects of Ketamine in Depression — Icahn School of Medicine at Mount Sinai, New YorkSleep Health in U.S. Marines — San Diego State University, San DiegoNeuroactive Steroid to Treat Depressed Mood: A Trial for People With HIV — Massachusetts General Hospital, BostonLeucine in Midlife Depression — Emory University Hospital, AtlantaFamily Acceptance Project Online (Pilot RCT) — University of Michigan, Ann ArborCombination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer — MD Anderson Cancer Center, HoustonNMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits — Washington University School of Medicine, St LouisCannabis for Palliative Care in Cancer — Anschutz Health Sciences Building, AuroraPsilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer — Ohio State University Comprehensive Cancer Center, Columbus5-HTP and Creatine for Depression R33 Phase — University of Utah Department of Psychiatry, Salt Lake CityProcesses and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression — Laureate Institute for Brain Research, TulsaKetamine Alcohol (in Treatment-Resistant Depression) — University of Iowa Health Care, Iowa CityPET Imaging Using the Tracer [18F]VAT to Assess the Antidepressant Effect of Nicotine. — Stony Brook University: Dept of Psychiatry, Stony BrookModulating Spinal Interoceptive Pathways to Evaluate Their Role and Therapeutic Potential in MDD Symptomatic Domains — Lindner Center of Hope, MasonPersonalized Ultrasonic Brain Stimulation for Depression (R61) — University of Utah, Salt Lake CityBezafibrateTreatment for Bipolar Depression: A Proof of Concept Study — The Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, BostonA Digital Intervention for Post-Stroke Depression and Executive Dysfunction — Weill Cornell Medical Center, New YorkPsilocybin Therapy for Depression in Parkinson's Disease — University of California, San Francisco, San FranciscoA New Intervention to Improve Function in Veterans With Anxiety and Depression — Durham VA Medical Center, Durham, NC, DurhamCognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab — Massachusetts General Hospital, BostonA Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression — Massachusetts General Hospital, Chelsea, ChelseaPET Imaging of Cyclooxygenase in Participants With Major Depressive Disorder (MDD) — National Institutes of Health Clinical Center, BethesdaThe Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects — VA Connecticut Healthcare System, West HavenJAK Signaling in Depression — Emory University, AtlantaIdentifying and Treating Depression in the Orthopaedic Trauma Population — Wake Forest University Health Sciences, Winston-SalemOpen-Label Psilocybin Study in Transdiagnostic Population — Connecticut Mental Health Center - Yale School of Medicine, New HavenNeurobiology of Suicide — National Institutes of Health Clinical Center, BethesdaRegulation of Affect and Physiology in Depression — University of Southern California, Los AngelesPsilocybin in Chronic Low Back Pain and Depression — Johns Hopkins University School of Medicine, BaltimoreStudy of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans — Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West HavenInvestigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — National Institutes of Health Clinical Center, BethesdaPsilocybin to Treat Depression in Spinal Cord Injury — James J. Peters Department of Veterans Affairs Medical Center, The BronxDopaminergic Therapy for Anhedonia - 2 — Emory University Hospital, AtlantaTraining Reward Responsiveness Through Virtual Reality — University of California, Los Angeles, Los Angeles[18F]PF-06445974 to Image PDE4B in Major Depressive Disorder Using PET — National Institutes of Health Clinical Center, BethesdaNeutralizing Interleukin (IL)-6 — Icahn School of Medicine at Mount Sinai, New YorkMindfulness-based Psilocybin Therapy for PTSD — The Ohio State University Medical Center, ColumbusPsilocybin rTMS for Treatment Resistant Depression — Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, AustinComputerized Cognitive Behavioral Therapies for Suicide Prevention and Depression — Eastern Colorado Health Care System, AuroraOrexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial — James J. Peters Veterans Affairs Medical Center, The BronxThe Role of mGluR5 in CBT-I — Stony Brook University: Dept of Psychiatry, Stony BrookAlpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response — Yale University, New Haven

Showing the 150 nearest — narrow your filters for fewer, closer studies.